The global polycystic ovarian syndrome treatment market was valued at $2,902 million in 2018, and is projected to reach $4,184 million by 2026, registering a CAGR of 4.7% from 2019 to 2026.
Polycystic ovary syndrome or PCOS is a hormonal disorder that is common among women of childbearing age. PCOS causes infrequent or prolonged menstrual cycle or excess male hormone levels. Presently, there is no cure for PCOS, however, medications are used to regulate menstrual cycle and manage symptoms of PCOS.
Major Key Players of the Polycystic Ovarian Syndrome Treatment Market are:
Allergan plc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Johnson and Johnson, Mylan N.V., Novartis AG, Pfizer Inc., SANOFI, Teva Pharmaceutical Industries
No comments:
Post a Comment